Vemurafenib induces senescence in acute myeloid leukemia and myelodysplastic syndrome by activating the HIPPO signaling pathway: implications for potential targeted therapy.
Fiche publication
Date publication
janvier 2024
Journal
Biology direct
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GUIDEZ Fabien
Tous les auteurs :
Zhou Q, Zhang J, Zhang J, Liang S, Cai D, Xiao H, Zhu Y, Xiang W, Rodrigues-Lima F, Chi J, Guidez F, Wang L
Lien Pubmed
Résumé
The outcome of Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) remain dismal despite the development of treatment. Targeted therapy is gaining more and more attention in improving prognosis.
Mots clés
AML, BRAF, HIPPO signaling pathway, MDS, Senescence, Vemurafenib
Référence
Biol Direct. 2024 01 4;19(1):6